ClinicalTrials.gg

Program

heat-labile enterotoxin, E coli

Also written as “AD17002” and “AD17002 + Formulation buffer”.

Its studies are mostly in COVID-19 · Rhinitis, Allergic, led by Advagene Biopharma.

Furthest: phase 3, since Aug 5, 20225 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Advagene Biopharma51 open or runningphase 3since Aug 5, 2022Aug 8, 2019none ahead

Also a collaborator on its studies: Clinipace Worldwide.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 8, 2019First study: phase 2 study in Rhinitis, AllergicFirst studyNCT04088721 · 48 enrolled · Taiwan
  2. Oct 4, 2021Phase 2 study in COVID-19NCT05069610 · 30 enrolled · Taiwan
  3. Aug 5, 2022Phase 3 study in COVID-19NCT05541510 · 180 enrolled · Indonesia
  4. Jul 26, 2023Phase 2 study in Pulmonary EosinophiliaNCT05985694 · 40 enrolled · Taiwan
  5. Sep 4, 2025Phase 2 study in Pulmonary EosinophiliaNCT07250594 · 126 planned · Taiwan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07250594Pulmonary Eosinophilia · Taiwan2Not yet recruitingOct 2026126
NCT05985694Pulmonary Eosinophilia · Taiwan2CompletedJan 28, 202540
NCT05541510COVID-19 · Indonesia3TerminatedAug 5, 2024180
NCT05069610COVID-19 · Taiwan2CompletedOct 31, 202330
NCT04088721Rhinitis, Allergic · Taiwan2CompletedJul 30, 202048

How it is read

Names in the registry

  • “AD17002”, 4 entries
  • “AD17002 + Formulation buffer”, 1 entry

Codes read as this program: AD17002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.